“Hepatitis b”的搜索结果，显示 381-390 项，共有 9258 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

3. 血液科- 临床试验- 妙佑医疗国际

   AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) B-cell NHL ... B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

5. 血液科- 临床试验- 妙佑医疗国际

   Inclusion Criteria are the following: age ≥ 18, blood cancer diagnosis (including B-ALL, multiple myeloma, and lymphoma), receiving a CAR-T product, able ...

6. 血液科- 临床试验- 妙佑医疗国际

   AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) B-cell NHL. Rochester, Minn. This is a Phase 2 global, multi-center, open-label study ...

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The purpose of this study is to provide access to CTL019 through Managed Access Program (MAP) for acute lymphoblastic leukemia (ALL) or diffuse large b-cell ...

8. 胆道闭锁- 诊断与治疗- 妙佑医疗国际

   Neonatal hepatitis. This is liver inflammation caused by infection or other factors. It can cause jaundice and dark urine but usually doesn't block the bile ...

9. 血液科- 临床试验- 妙佑医疗国际

   ... B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Additional cohorts include subjects with B-cell primary or secondary central nervous ...

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    Also, we will evaluate whether the peripheral blood immune cell function is different in B/AA prostate cancer patients with metastatic disease as compared with ...